CorriXR Therapeutics
Pre-clinicalCorriXR Therapeutics is an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology to overcome drug resistance in solid tumors.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $32.2M
About
CorriXR Therapeutics is an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology to overcome drug resistance in solid tumors.
OncologyCell Therapy
Funding History
2Total raised:$32.2M
Series A$28MFeb 15, 2024
Seed$4.2MAug 15, 2022